Automated detection of residual cells after sex-mismatched stem-cell transplantation evidence for presence of disease-marker negative residual cells

Molecular Cytogenetics

Volumn 2, Issue 1, 2009, Pages

  Erlecke, Jörn ^a   Hartmann, Isabell ^a   Hoffmann, Martin ^c   Kroll, Torsten ^d   Starke, Heike ^a   Heller, Anita ^a   Gloria, Alexander ^a   Sayer, Herbert G ^d   Johannes, Tilman ^e   Claussen, Uwe ^a   Liehr, Thomas ^a   Loncarevic, Ivan F ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Clondiag Chip Technologies   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Centre Jena   (Germany)

^e MetaSystems   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOANALYSIS; BLOOD CELL; BLOOD SAMPLING; BONE MARROW; CHILD; CHIMERA; CONTROLLED STUDY; DEVICE; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HEMATOLOGIC MALIGNANCY; HISTOGRAM; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SEX CHROMOSOME; SURVIVAL RATE; TRISOMY 8;

EID: 67650733240     PISSN: None     EISSN: 17558166     Source Type: Journal    
DOI: 10.1186/1755-8166-2-12     Document Type: Article

References (46)

1. Cancer in Germany, 20032004. Incidence and Trends. WU Batzler K Giersiepen S Hentschel G Husmann P Kaatsch A Katalinic J Kieschke K Kraywinkel M Meyer R Stabenow C Stegmaier J Bertz J Haberland U Wolf, Robert Koch Institute and Association of Population-based Cancer Registries in Germany. Berlin 6 2008
2. Chimerism status is a useful predictor of relaps after allogeneic stem cell transplantationfor acute leukemia. M Barrios A Jiménez-Velasco J Rman-Gmez ME Madrigal JA Castillejo A Torres A Heiniger, Haematologica 2003 88 801 810 12857560 (Pubitemid 36896140)
3. Early establishment of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation in comparison with allogeneic bone marrow transplantation. S Nakao W Zeng H Yamazaki H Wang A Takami N Sugimori Y Miura S Shiobara T Matsuda Y Shinagawa M Harada, Eur J Haematol 1999 62 265 270 10227460 (Pubitemid 29173278)
4. Kinetics of chimerism during the early post-transplantat period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. J Dubovsky H Daxberger G Fritsch D Printz C Peters S Matthes H Gadner T Lion, Leukemia. 1999 13 12 2060 2069 10.1038/sj/leu/2401603
5. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. J Mattsson M Uzunel L Tammik J Aschan O Ringdén, Leukemia 2001 15 1976 1985 11753621 (Pubitemid 33115007)
6. Quantitative analysis of chimerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite PCR. P Hancock NJ Goulden A Oakhill CG Steward, Leukemia 2003 17 247 251 10.1038/sj.leu.2402759 12529688
7. Hematopoietic chimerism after allogeneic stem cell transplantation: a comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization. J Jolkowska A Pieczonka T Strabel D Boruczkowski J Wachowiak P Bader M Witt, BMC Blood Disord 2005 5 1 15642114 10.1186/1471-2326-5-1
8. From Genes to therapy: the case of Philadelphia chromosome-positive leukemias. D Cilloni A Guerrasio E Giugliano P Scaravaglio G Volpe G Rege-Cambrin G Saglio, Ann N Y Acad Sci 2002 963 306 312 12095956 (Pubitemid 34721723)
9. Genomic Imbalances in CML Blast Crisis: 8q24.12-q24.13 Segment Identified as a Common Region of Over-Representation. SM Gribble AG Reid I Roberts C Grace AR Green EP Nacheva, Genes Chromosomes Cancer. 2003 37 4 346 358 10.1002/gcc.10173 12800146
10. Cytogenetic, morphological, and immunophenotypic patterns in Omani patients with de novo acute myeloid leukemia. AM Udamaykura AV Pathare S Al-Kindi H Khan JU Rehmen f Zia A Al-Ghazaly N Nusrut MI Khan YA Wali Z Al-Lamki D Dennison JA Raeburn, Cancer Genet Cytogenet 2007 177 89 94 10.1016/j.cancergencyto.2007.05.014 17854660
11. Detection of minimal residual desease after sex-mismatch bone marrow tranplantation in chronic myelogenous leukemia by fluorescence in situ hybridization. A Nagler S Slavin S Yarkoni M Fejgin A Amiel, Cancer Genet Cytogenet 1994 73 130 133 10.1016/0165-4608(94)90196-1 8174087
12. Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies. S Tamura K Saheki H Takatsuka H Wada Y Fujimori T Okamoto Y Takemoto T Hashimoto-Tamaoki J Furuyama E Kakishita, Ann Hematol 2000 79 622 626 10.1007/s002770000204 11131921 (Pubitemid 30943528)
13. Mixed chimerism of bone marrow CD34+ progenitor cells (genotyping, bcr/abl analysis) after allogeneic transplantation for chronic myelogenous leukemia. J Thiele C Wickenhauser HM Kvasnicka E Varus S Kleppe DW Beelen UW Schaefer, Transplantation 2002 74 982 986 10.1097/00007890-200210150-00015 12394842 (Pubitemid 35191248)
14. FISH analysis of native smears from bone marrow and blood for the monitoring of chimerism and clonal markers after stem cell transplantation in children. M Führer M Gerusel-Bleck N Konstantopoulos C Bender-Goetze JU Walther, Int J Mol Med 2005 15 291 297 15647846
15. Mixed chimaerism; detection and significance following BMT. SR McCann M Lawler, Bone Marrow Transplant 1993 11 91 94 8435668 (Pubitemid 23058289)
16. Lineage-specific chimaerism quantifikation after T-cell depleted peripheral blood stem cell transplantation. I Bũo B Anta E Moreno-Lopéz P Balsalobre A Balas F García-Sanchez D Serrano R Carrion A Gmez-Pineda J Díez-Martín, Leuk Lymphoma 2003 44 659 667 10.1080/1042819031000067738 12769344
17. Increasing mixed chimerism is an important prognostic factor for unfavourable outcome in children with acute lymphoblastic leukemia after allogeneic stem cell tranplantation: possible role for pre-emptive immunotherapy. P Bader H Kreyenberg W Hölle G Dückers R Handgretinger P Lang B Kremens D Dilloo KW Sykora M Schrappe C Niemeyer A Von Stackelberg B Gruhn G Henze J Greil D Niethammer K Dietz JF Beck T Klingebiel, J Clin Oncol 2004 22 1696 1705 10.1200/JCO.2004.05.198 15117992
18. Automated fluorescent in situ hybridization (FISH) analysis of t(9;22)(q34;q11) in interphase nuclei. B Kajtar G Mehes T Lörch L Deak M Kneifne D Alpar L Pajor, Cytometry A 2006 69 506 514 16646048 (Pubitemid 44651337)
19. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. P Bader J Beck A Frey PG Schlegel H Hebarth R Handgretinger H Einsele C Niemeyer N Benda C Faul L Kanz D Niethammer T Klingebiel, Bone Marrow Transplant 1998 21 487 495 10.1038/sj.bmt.1701119 9535041 (Pubitemid 28107956)
20. Fluorescence in situ hybridization with X and Y chromosome probes for cytogenetic studies on bone marrow cells after opposite sex transplantation. Bone Marrow. GW Dewald CR Schad ER Christensen ME Law AL Zinsmeister PG Stalboerger SM Jalal RC Ash RB Jenkins, Bone Marrow Transplant. 1993 12 2 149 154 8401362 (Pubitemid 23243417)
21. A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell tranplantation. I Bũo P Nava A Simon M González-Rivera JL Jiménez P Balsalobre D Serrano R Carrin A Gmez-Pineda J Díez-Martín, Haematologica. 2005 90 10 1373 1379 16219574 (Pubitemid 41503653)
22. Molecular analysis of lineage-specific chimerism and minimla residual desease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronoc myeloid leukaemia: increasing mixed chimerism and p190 (BCR-ABL) detection precede cytogenetic relaps. J Serrano J Román J Sánchez A Jiménez JA Castillejo C Herrera MG Gonzalez L Reina MC Rodriguez MA Alvarez J Maldonado A torres, Blood 2000 15 2659 2665 (Pubitemid 30210547)
23. Chimerism testing and detection of minimal residual disease after allogeneic hematopietic transplantation using the DuetTM (BioView) combined morphological and cytogenetical analysis. L Trakthenbrot M Reichart A Shimoni, Leukemia 2002 16 1419 1422 10.1038/sj.leu.2402604
24. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. DW Bianchi GK Zickwolf GJ Weil S Sylvester MA DeMaria, Proc Natl Acad Sci USA 1996 93 705 708 8570620 10.1073/pnas.93.2.705
25. Male DNA in female donor apharesis and CD34-enriched products. KM Adams NC Lambert S Heimfeld TS Tylee JM Pang TD Erickson JL Nelson, Blood 2003 102 3845 3847 10.1182/blood-2003-05-1570 12869496
26. Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. RB Jenkins MM Le Beau WJ Kraker TJ Borell PG Stalboerger EM Davis L Penland A Fernald R Espinosa 3rd DJ Schaid, Blood 1992 79 3307 3315 1596571
27. Detection and monitoring of trisomy 8 by fluorescence in situ hybridization in acute myeloid leukemia: a multicentric study. A Cuneo R Bigoni MG Roberti A Bardi GM Rigolin N Piva M Mancini M Nanni G Alimena C Mecucci C Matteucci R La Starza P Bernasconi P Cavigliano E Genini A Zaccaria N Testoni C Carboni G Castoldi, Haematologica 1998 83 21 26 9542319 (Pubitemid 28096498)
28. Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization. A Amiel S Yarkoni S Slavin R Or H Lorberboum-Galski M Fejgin A Nagler, Cancer Genet Cytogenetb 1994 76 59 64 10.1016/0165-4608(94)90073-6
29. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia. D Van den Berg M Wessman L Murray J Tong B Chen S Chen D Simonetti J King G Yamasaki R DiGiusto D Gearing C Reading, Blood 1996 87 4348 4357 8639795 (Pubitemid 26152275)
30. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon trteatment: a new strategiy for remission assessment. J Mühlmann J Thaler W Hilbe O Bechter M Erdel G Utermann HC Duba, Genes Chromosomes Cancer 1998 21 90 100 10.1002/(SICI)1098-2264(199802)21:2<90:: AID-GCC3>3.0.CO;2-2 9491319 (Pubitemid 28081234)
31. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization. A Chase F Grand JG Zhang N Blackett J Goldman M Gordon, Genes Chromosomes Cancer 1997 18 246 253 10.1002/(SICI)1098- 2264(199704)18:4<246::AID-GCC2>3.0.CO;2-0 9087564 (Pubitemid 27161394)
32. Application of fluorescence in situ hybridization to detect residual leukemic cells with 9;22 and 15;17 translocations. K Tanaka M Arif M Eguchi TS Kumaravel R Ueda R Ohno K Iwato T Kyo H Dohy N Kamada, Leukemia 1997 11 436 440 10.1038/sj.leu.2400583 9067586 (Pubitemid 27120996)
33. High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia. H Rieder C Bonwetsch LA Janssen J Maurer JW Janssen S Schwartz WD Ludwig W Gassmann CR Bartram E Thiel H Löffler N Gökbuget D Hoelzer C Fonatsch, Leukemia 1998 12 1473 1481 10.1038/sj.leu.2401127 9737699 (Pubitemid 28442397)
34. Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization. N Cohen I Novikov I Hardan A Esa F Brok-Simoni N Amariglio G Rechavi I Ben-Bassat L Trakhtenbrot, Cancer Genet Cytogenet 2000 123 102 108 10.1016/S0165-4608(00)00315-0 11150599
35. Fluorescence in situ hybridization BCR/ABL fusion signal rate in interphase nuclei of healthy volunteer donors: a test study for establishing false positive rate. JR Kowalczyk A Gaworczyk D Winnicka M Lejman M Babicz, Cancer Genet Cytogenet 2003 142 51 55 10.1016/S0165-4608(02)00767-7 12660033
36. Counting, measuring, and mapping in FISH-labelled cells: sample size considerations and implications for automation. AD Carothers, Cytometry 1994 16 298 304 10.1002/cyto.990160403 7988292
37. FISH detection of mixed chimerism in 33 patients submitted to bone marrow transplantation. G Palka L Stuppia P Di Bartolomeo E Morizio R Peila PG Franchi G Calarese, Bone Marrow Transplant 1996 17 231 236 8640172 (Pubitemid 26057313)
38. Characterization of lineage-specific chimaerism in patients with acute leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. P Bader K Stoll S Huber A Geiselhart R Handgretinger C Niemeyer H Einsele PG Schlegel D Niethammer J Beck T Klingebiel, Br J Haematol 2000 108 761 768 10.1046/j.1365-2141.2000.01927.x 10792281
39. Minimal residual desease detection after allogeneic stem cell transplantation is correlatet to relapse in patients with acute lymphoblastic leukemia. M Uzunel M Jaksch J Matisson O Ringdén, Br J Haematol 2003 122 788 794 10.1046/j.1365-2141.2003.04495.x 12930390
40. Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depletet bone marrow is not associatet with a higher incidence of relapse. A Schattenberg T de Witte M Salden J Vet B Van Dijk D Smeets J Hoogenhout C Haanen, Blood 1989 73 1367 1372 2564791 (Pubitemid 19107446)
41. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. N Schaap A Schattenberg E Mensink F Preijers F Hillegers R Knops A Pennings J Boezeman A Geurts van Kessel B de Pauw T de Witte, Leukemia 2002 16 13 21 10.1038/sj.leu.2402343 11840258 (Pubitemid 34105594)
42. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis. A Shimoni A Nagler C Kaplinsky M Reichart A Avigdor I Hardan M Yeshurun M Daniely Y Zilberstein N Amariglio F Brok-Simoni G Rechavi L Trakhtenbrot, Leukemia 2002 16 1413 1422 10.1038/sj.leu.2402581 12145678
43. Human chromosomes: principles and techniques. RS Verma A Babu, McGraw-Hill, New York 2 1994
44. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. D Pinkel T Straume JW Gray, Proc Natl Acad Sci USA 1989 83 2934 2938 10.1073/pnas.83.9.2934
45. Allogenic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. N Kröger M Bornhäuser G Ehinger R Schwerdtfeger H Biersack HG Sayer H Wandt K Schäfer-Eckhardt J Beyer M Kiehl AR Zander German Cooperative Transplant Study Group, Ann Hematol 2003 82 336 342 10.1007/s00277-003-0654-9 12728337
46. Full-intensity and reduced intensity allogeneic stem cell transplantation in AML. CF Craddock, Bone Marrow Transplant 2008 41 415 423 10.1038/sj.bmt.1705975 18209726